Eiko Lifesciences Ltd

Eiko Lifesciences Ltd

Eiko Lifesciences Ltd has announced the closure of its trading window for designated persons and their immediate relatives from October 1, 2026, until 48 hours after the Board Meeting where the Un-Audited Standalone and Consolidated Financial Results for the quarter ended September 30, 2026, will be considered.

Eiko Lifesciences Ltd

Eiko Lifesciences Ltd has announced the voting results and scrutinizer's report of its 49th Annual General Meeting (AGM) held on September 22, 2026, through video conference. The report confirms that the electronic copy of the notice convening the AGM and explanatory statement along with the annual report for FY 2025-26 were sent to shareholders, and the remote e-voting and e-voting process was conducted fairly and transparently.

Eiko Lifesciences Ltd

Eiko LifeSciences Limited held its 49th Annual General Meeting (AGM) on September 22, 2026, through video conferencing. The meeting was attended by 25 members, and the proceedings were summarized and attached to the announcement. The meeting transacted on several items, including the adoption of audited financial statements, the re-appointment of a director, and the approval of material related party transactions.

Eiko Lifesciences Ltd

Eiko Lifesciences Ltd has sent a letter to the BSE, informing them that the company has provided a weblink and QR code for accessing the Notice convening the 49th Annual General Meeting (AGM) and the Annual Report for the Financial Year 2025-26, to shareholders who have not registered their email addresses or hold physical shares.

Eiko Lifesciences Ltd

Eiko Lifesciences Ltd has announced the publication of a newspaper advertisement for its 49th Annual General Meeting (AGM) scheduled to be held on September 22, 2026, through video conference.

Eiko Lifesciences Ltd

Eiko Lifesciences Ltd has announced its 49th Annual General Meeting to be held on September 22, 2026, through video conferencing. The company has also released its annual report for the financial year 2025-26, which includes a strong growth in revenue and profit after tax, with an EBITDA margin improvement to 11.19%. The company has also made a strategic acquisition in SSM Formulations Private Limited, marking a significant step in its evolution towards a more integrated chemical and pharmaceutical enterprise.

Eiko Lifesciences Ltd

Eiko Lifesciences Ltd has announced its 49th Annual General Meeting (AGM) to be held on September 22, 2026, through video conferencing. The meeting will consider and adopt the audited standalone and consolidated financial statements for the financial year ended March 31, 2026. Resolutions for the re-appointment of a director, appointment of an independent director, and approval of material related party transactions will also be considered.

Eiko Lifesciences Ltd

Eiko Lifesciences Ltd announced the resignation of Ms. Hasti Doshi as Independent Director due to other career commitments, effective from the closing of business hours on 24th August, 2026.

Eiko Lifesciences Ltd

Eiko Lifesciences Ltd has appointed Mr. Suraj Mahadev Gaikwad as Additional Director (Independent and Non-Executive) to hold the office up to the date of the ensuing Annual General Meeting of the Company, and thereafter as an Independent Director of the Company for a term of 5 (five) years, subject to the approval of shareholders.

Eiko Lifesciences Ltd

Eiko Lifesciences Ltd announced the resignation of Ms. Hasti Doshi as Independent Director due to other career commitments, and the appointment of Mr. Suraj Mahadev Gaikwad as Additional Director (Independent and Non-Executive) to hold office up to the date of the ensuing Annual General Meeting, and thereafter as an Independent Director for a term of 5 years. The company also recommended the re-appointment of Mr. Bhavesh Dhirajlal Tanna as a Director, and convened the 49th Annual General Meeting for September 22, 2026.

Eiko Lifesciences Ltd

Eiko Lifesciences Ltd has received communications and recovery proceedings from IDBI Bank regarding an alleged corporate guarantee of ₹58 lakhs issued by the company's erstwhile entity in 1986. The company disputes the claim and is pursuing legal remedies.

Eiko Lifesciences Ltd

Eiko Lifesciences Ltd has converted 305,000 warrants into 305,000 equity shares at Rs. 55 each, increasing its issued capital to Rs. 146,508,540. The shares were allotted to promoters and non-promoters on a preferential basis.

Eiko Lifesciences Ltd

Eiko Lifesciences Ltd has published its unaudited financial results for the quarter ended 30th June, 2026, as approved by the Board of Directors on 12th August, 2026.

Eiko Lifesciences Ltd

Eiko Lifesciences Ltd has announced its un-audited standalone and consolidated financial results for the quarter ended 30th June, 2026, along with a limited review report issued by its statutory auditors.

Eiko Lifesciences Ltd

Eiko Lifesciences Ltd has scheduled a board meeting on 12th August 2026 to consider and approve the unaudited standalone and consolidated financial results for the quarter ended 30th June 2026.